Benchmark Reaffirms Buy Rating for Humacyte (NASDAQ:HUMA)

Humacyte (NASDAQ:HUMA)‘s stock had its “buy” rating reaffirmed by research analysts at Benchmark in a research note issued to investors on Thursday,Benzinga reports.

A number of other analysts also recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price (up from $12.00) on shares of Humacyte in a research note on Friday, December 20th. D. Boral Capital restated a “buy” rating and set a $25.00 price objective on shares of Humacyte in a research report on Wednesday. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Humacyte presently has an average rating of “Buy” and an average target price of $13.71.

Humacyte Price Performance

Shares of NASDAQ:HUMA traded up $0.34 during midday trading on Thursday, hitting $3.77. The company had a trading volume of 852,719 shares, compared to its average volume of 2,218,799. Humacyte has a twelve month low of $2.81 and a twelve month high of $9.97. The stock has a market cap of $473.86 million, a price-to-earnings ratio of -2.78 and a beta of 1.30. The business’s 50-day simple moving average is $4.38 and its 200-day simple moving average is $4.99.

Institutional Trading of Humacyte

Institutional investors and hedge funds have recently bought and sold shares of the stock. Vontobel Holding Ltd. acquired a new stake in shares of Humacyte during the fourth quarter valued at about $50,000. Petros Family Wealth LLC purchased a new position in Humacyte during the 4th quarter valued at about $50,000. Syon Capital LLC acquired a new position in Humacyte in the 4th quarter valued at about $54,000. Brookstone Capital Management acquired a new position in Humacyte in the 4th quarter valued at about $56,000. Finally, ACT Wealth Management LLC purchased a new stake in Humacyte during the fourth quarter worth about $57,000. 44.71% of the stock is currently owned by hedge funds and other institutional investors.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.